Daily Management Review

Recognising The ‘Global Healthcare Challenge’ Glaxo Loosens Its Patents


10/22/2016


GSK seeks for ways to “contribute” in easing “access to medicines” worldwide.



Recognising The ‘Global Healthcare Challenge’ Glaxo Loosens Its Patents
Last week, GlaxoSmithKline, the giant among the “London-listed pharmaceuticals”, reported of its “evolving” approach towards “filing and enforcing patents”, whereby reflecting “a country’s wealth” through “IP protection”.
 
Before the “UN High Level Panel” meeting discussing on “Access to Medicines”, the pharmaceutical informed that it will not “file patents for its medicines” in the countries where the either the income is low or is among the “least developed” countries. In this way, other companies will get a chance to create “cheaper generic versions” of Glaxo’s medicines for selling in those countries.
 
However, when the question comes to the “lower middle income countries”, Glaxo decides to file patent, although it will be offer license or agree to allow license for the sale of “generic versions of its medicines” over a decade. In fact, Glaxo has plans of seeking a small portion of royalty on the above mentioned sales.
 
Eventually, for the “high income”, “upper middle income” as well as G20 countries, Glaxo will maintain its “full patent protection”, while:
“Any Glaxo drugs on the WHO’s list of essential medicines will be included in these changes”.
 
In the words of the chief executive e officer of Glaxo, Sir Andrew Witty:
“In itself, IP is not a barrier to access to medicines. However, we recognise that the global healthcare challenge requires us to be flexible in our approach and responsive to different needs, particularly as the disease burden shifts from infectious to non-communicable diseases.
“We continuously look at ways that GSK can further contribute to increasing access to medicines.”
 
Moreover, Glaxo made an announcement of allowing the “developing countries” to access its “next-generation cancer drugs”, whereby it will allow “competitors to access its intellectual property through the UN-backed Medicines Patent Pool”.
 
 
 
 
 
 
References:
http://www.digitallook.com/







Science & Technology

Gene Editing of Human Embryo Could Find ‘Moral’ Grounds: UK’s Ethics Council

Baidu comes up with a self-driving bus

Developing countries are stepping up their own space programs

McAfee: Number of cybercrime attacks skyrocketed

RemoveDebris Mission To Clear Debris Of In Orbit Over Earth

British experts: Online gambling is dangerous

Vodafone Chooses ‘Highly Trafficked Urban’ Space As Its 5G Testing Grounds

Space To Become A Travel Destination By 2022

Dream Of Immortality Can Be Realised By 2045

Predicting A Patient’s Death Might Be Possible With Google’s Machine Learning Tool

World Politics

World & Politics

Germany asks to return € 4 thousand subsidies for the purchase of Tesla

Was Trump's visit to the UK the last straw?

Prime Minister May Could Alter Brexit Strategies, Said Ress-Mogg

Le Maire: The US refused to release France from anti-Iran sanctions

One Belt, One Road is facing difficulties around the world

Qatar to raise $ 4 billion to buy Eurofighter Typhoon jets

The UK sets to turn all cars zero-emission by 2030

Brexit Minister’s Resignation States May’s Brexit Policies Weakening The Country’s Stance